Undo HIV: Understanding and targeting the active HIV reservoir
Official title: UNDO-HIV: UNDerstanding and Obliterating the active HIV reservoir
Funded at J. David Gladstone Institutes · NIH-11470917 · Data updated 2026-11-12
Aims to map and ultimately eliminate the HIV cells that stay active despite therapy to improve long-term control of HIV in people living with HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | July 15, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $896,029 |
| NIH project number | 1R01AI203534-01 |
| Project ID | NIH-11470917 on NIH RePORTER |
Who could benefit from this research
✓Could help
People living with HIV on ART whose viral reservoir includes translationally-active HIV-infected cells.
✕Less likely to help
People without HIV or those not undergoing ART-related reservoir research would not directly benefit.
What this research studies
This project uses new single-cell and imaging technologies to identify HIV-infected cells that remain translationally active even under antiretroviral therapy. It will characterize these cells at the RNA and protein levels and study their behavior in tissues to understand how they evade the immune system. The team will apply three innovative tools to banked and newly collected blood and tissue samples from people living with HIV to pinpoint features that could be targeted by future therapies. The goal is to guide strategies that could reduce the viral reservoir and improve treatment outcomes.
Why it matters
Potential benefit: If successful, the work could inform therapies that shrink the HIV reservoir and bring people closer to durable viral suppression.
How similar studies have gone: Preliminary tools and methods have shown promise in identifying active reservoir cells, and this project builds on those advances with more comprehensive single-cell and tissue analyses.
Where this research is happening
-
J. David Gladstone Institutes
San Francisco, United States Active
Researchers
- Principal investigator: Roan, Nadia R — J. David Gladstone Institutes
- Study coordinator: Roan, Nadia R
Related research
Other NIH-funded projects on the same topics.
-
HOPE: a new approach to silencing HIV and preventing rebound
A large NIH grant is testing a combination strategy to turn off HIV genes in people on treatment so the virus stays gone and health improves.
-
TREM2 and TYROBP in Alzheimer's brain network changes
This grant looks at how microglial proteins TREM2 and TYROBP influence brain network excitability in people with Alzheimer's disease and related dementias.
-
Commensal respiratory viruses and how they interact with the human airway
A small NIH grant is exploring how the normal viruses living in our airways interact with our cells to stay harmless and support healthy breathing.
-
Targeted delivery systems to edit blood stem cells
Aims to safely deliver genome-editing tools to blood stem cells to treat diseases like acute myeloid leukemia.
-
Regionally Specific Transplants to Restore Breathing After Cervical Spine Injury
A patient-focused look at a study that aims to repair breathing circuits after cervical spinal cord injury using stem-cell–derived nerve cells and targeted neuromodulation.
-
Machine learning to understand how noncoding DNA variants affect heart development
A new AI-based tool is being developed to predict how noncoding genetic changes influence heart development and contribute to congenital heart disease in children.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.